http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 27 Aug 2026 14:16:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++3++++++++++AN2+Therapeutics%2C+Inc.++++For%3A+Aug+24++Filed+by%3A+Trenor+Cameron+C.+III/26988808.html si-local-file:///var/storage/secattach/20260827/26988808.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++AN2+Therapeutics%2C+Inc.++++For%3A+Aug+24++Filed+by%3A+Trenor+Cameron+C.+III/26988808.html Thu, 27 Aug 2026 14:16:00 -0400 ANTX O.53806153 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++AN2+Therapeutics%2C+Inc.++++For%3A+Aug+24++Filed+by%3A+Trenor+Cameron+C.+III/26988808.html si-local-file:///var/storage/secattach/20260827/26988808.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++AN2+Therapeutics%2C+Inc.++++For%3A+Aug+24++Filed+by%3A+Trenor+Cameron+C.+III/26988808.html Thu, 27 Aug 2026 14:16:00 -0400 ANTX O.53806153 http://www.streetinsider.com/Management+Changes/AN2+Therapeutics+names+Cameron+Trenor+as+chief+medical+officer/26964064.html <p>AN2 Therapeutics, Inc. (Nasdaq: ANTX) has appointed Cameron Trenor, M.D., as chief medical officer, the clinical-stage biopharmaceutical company announced in a press release.</p> <p>Dr. Trenor most recently served as chief medical officer at Cellarity, where he oversaw the company's first investigational new drug submission and the initiation of a global first-in-human clinical study. Before that, he was executive medical director at Forma Therapeutics, which was later acquired by Novo Nordisk, where he led global clinical development for etavopivat through Phase 3. Earlier in his career, he held clinical and translational roles at Novartis Institutes for BioMedical Research.</p> <p>Dr. Trenor continues to practice http://www.streetinsider.com/Management+Changes/AN2+Therapeutics+names+Cameron+Trenor+as+chief+medical+officer/26964064.html Mon, 24 Aug 2026 07:00:58 -0400 A.13777776 A.20922990 A.24325885 A.35954321 A.39894163 A.50114147 A.50201820 ANTX O.00048977 O.01270742 O.02095106 O.12960673 O.20314535 O.20737027 O.47915205 O.53806153 http://www.streetinsider.com/Management+Changes/AN2+Therapeutics+names+Cameron+Trenor+as+chief+medical+officer/26964064.html <p>AN2 Therapeutics, Inc. (Nasdaq: ANTX) has appointed Cameron Trenor, M.D., as chief medical officer, the clinical-stage biopharmaceutical company announced in a press release.</p> <p>Dr. Trenor most recently served as chief medical officer at Cellarity, where he oversaw the company's first investigational new drug submission and the initiation of a global first-in-human clinical study. Before that, he was executive medical director at Forma Therapeutics, which was later acquired by Novo Nordisk, where he led global clinical development for etavopivat through Phase 3. Earlier in his career, he held clinical and translational roles at Novartis Institutes for BioMedical Research.</p> <p>Dr. Trenor continues to practice http://www.streetinsider.com/Management+Changes/AN2+Therapeutics+names+Cameron+Trenor+as+chief+medical+officer/26964064.html Mon, 24 Aug 2026 07:00:58 -0400 A.13777776 A.20922990 A.24325885 A.35954321 A.39894163 A.50114147 A.50201820 ANTX O.00048977 O.01270742 O.02095106 O.12960673 O.20314535 O.20737027 O.47915205 O.53806153 http://www.streetinsider.com/Management+Changes/AN2+Therapeutics+names+Cameron+Trenor+as+chief+medical+officer/26964064.html <p>AN2 Therapeutics, Inc. (Nasdaq: ANTX) has appointed Cameron Trenor, M.D., as chief medical officer, the clinical-stage biopharmaceutical company announced in a press release.</p> <p>Dr. Trenor most recently served as chief medical officer at Cellarity, where he oversaw the company's first investigational new drug submission and the initiation of a global first-in-human clinical study. Before that, he was executive medical director at Forma Therapeutics, which was later acquired by Novo Nordisk, where he led global clinical development for etavopivat through Phase 3. Earlier in his career, he held clinical and translational roles at Novartis Institutes for BioMedical Research.</p> <p>Dr. Trenor continues to practice http://www.streetinsider.com/Management+Changes/AN2+Therapeutics+names+Cameron+Trenor+as+chief+medical+officer/26964064.html Mon, 24 Aug 2026 07:00:58 -0400 A.13777776 A.20922990 A.24325885 A.35954321 A.39894163 A.50114147 A.50201820 ANTX O.00048977 O.01270742 O.02095106 O.12960673 O.20314535 O.20737027 O.47915205 O.53806153 http://www.streetinsider.com/Management+Changes/AN2+Therapeutics+names+Cameron+Trenor+as+chief+medical+officer/26964064.html <p>AN2 Therapeutics, Inc. (Nasdaq: ANTX) has appointed Cameron Trenor, M.D., as chief medical officer, the clinical-stage biopharmaceutical company announced in a press release.</p> <p>Dr. Trenor most recently served as chief medical officer at Cellarity, where he oversaw the company's first investigational new drug submission and the initiation of a global first-in-human clinical study. Before that, he was executive medical director at Forma Therapeutics, which was later acquired by Novo Nordisk, where he led global clinical development for etavopivat through Phase 3. Earlier in his career, he held clinical and translational roles at Novartis Institutes for BioMedical Research.</p> <p>Dr. Trenor continues to practice http://www.streetinsider.com/Management+Changes/AN2+Therapeutics+names+Cameron+Trenor+as+chief+medical+officer/26964064.html Mon, 24 Aug 2026 07:00:58 -0400 A.13777776 A.20922990 A.24325885 A.35954321 A.39894163 A.50114147 A.50201820 ANTX O.00048977 O.01270742 O.02095106 O.12960673 O.20314535 O.20737027 O.47915205 O.53806153 http://www.streetinsider.com/Management+Changes/AN2+Therapeutics+names+Cameron+Trenor+as+chief+medical+officer/26964064.html <p>AN2 Therapeutics, Inc. (Nasdaq: ANTX) has appointed Cameron Trenor, M.D., as chief medical officer, the clinical-stage biopharmaceutical company announced in a press release.</p> <p>Dr. Trenor most recently served as chief medical officer at Cellarity, where he oversaw the company's first investigational new drug submission and the initiation of a global first-in-human clinical study. Before that, he was executive medical director at Forma Therapeutics, which was later acquired by Novo Nordisk, where he led global clinical development for etavopivat through Phase 3. Earlier in his career, he held clinical and translational roles at Novartis Institutes for BioMedical Research.</p> <p>Dr. Trenor continues to practice http://www.streetinsider.com/Management+Changes/AN2+Therapeutics+names+Cameron+Trenor+as+chief+medical+officer/26964064.html Mon, 24 Aug 2026 07:00:58 -0400 A.13777776 A.20922990 A.24325885 A.35954321 A.39894163 A.50114147 A.50201820 ANTX O.00048977 O.01270742 O.02095106 O.12960673 O.20314535 O.20737027 O.47915205 O.53806153 http://www.streetinsider.com/Management+Changes/AN2+Therapeutics+names+Cameron+Trenor+as+chief+medical+officer/26964064.html <p>AN2 Therapeutics, Inc. (Nasdaq: ANTX) has appointed Cameron Trenor, M.D., as chief medical officer, the clinical-stage biopharmaceutical company announced in a press release.</p> <p>Dr. Trenor most recently served as chief medical officer at Cellarity, where he oversaw the company's first investigational new drug submission and the initiation of a global first-in-human clinical study. Before that, he was executive medical director at Forma Therapeutics, which was later acquired by Novo Nordisk, where he led global clinical development for etavopivat through Phase 3. Earlier in his career, he held clinical and translational roles at Novartis Institutes for BioMedical Research.</p> <p>Dr. Trenor continues to practice http://www.streetinsider.com/Management+Changes/AN2+Therapeutics+names+Cameron+Trenor+as+chief+medical+officer/26964064.html Mon, 24 Aug 2026 07:00:58 -0400 A.13777776 A.20922990 A.24325885 A.35954321 A.39894163 A.50114147 A.50201820 ANTX O.00048977 O.01270742 O.02095106 O.12960673 O.20314535 O.20737027 O.47915205 O.53806153 http://www.streetinsider.com/Management+Changes/AN2+Therapeutics+names+Cameron+Trenor+as+chief+medical+officer/26964064.html <p>AN2 Therapeutics, Inc. (Nasdaq: ANTX) has appointed Cameron Trenor, M.D., as chief medical officer, the clinical-stage biopharmaceutical company announced in a press release.</p> <p>Dr. Trenor most recently served as chief medical officer at Cellarity, where he oversaw the company's first investigational new drug submission and the initiation of a global first-in-human clinical study. Before that, he was executive medical director at Forma Therapeutics, which was later acquired by Novo Nordisk, where he led global clinical development for etavopivat through Phase 3. Earlier in his career, he held clinical and translational roles at Novartis Institutes for BioMedical Research.</p> <p>Dr. Trenor continues to practice http://www.streetinsider.com/Management+Changes/AN2+Therapeutics+names+Cameron+Trenor+as+chief+medical+officer/26964064.html Mon, 24 Aug 2026 07:00:58 -0400 A.13777776 A.20922990 A.24325885 A.35954321 A.39894163 A.50114147 A.50201820 ANTX O.00048977 O.01270742 O.02095106 O.12960673 O.20314535 O.20737027 O.47915205 O.53806153 http://www.streetinsider.com/Management+Changes/AN2+Therapeutics+names+Cameron+Trenor+as+chief+medical+officer/26964064.html <p>AN2 Therapeutics, Inc. (Nasdaq: ANTX) has appointed Cameron Trenor, M.D., as chief medical officer, the clinical-stage biopharmaceutical company announced in a press release.</p> <p>Dr. Trenor most recently served as chief medical officer at Cellarity, where he oversaw the company's first investigational new drug submission and the initiation of a global first-in-human clinical study. Before that, he was executive medical director at Forma Therapeutics, which was later acquired by Novo Nordisk, where he led global clinical development for etavopivat through Phase 3. Earlier in his career, he held clinical and translational roles at Novartis Institutes for BioMedical Research.</p> <p>Dr. Trenor continues to practice http://www.streetinsider.com/Management+Changes/AN2+Therapeutics+names+Cameron+Trenor+as+chief+medical+officer/26964064.html Mon, 24 Aug 2026 07:00:58 -0400 A.13777776 A.20922990 A.24325885 A.35954321 A.39894163 A.50114147 A.50201820 ANTX O.00048977 O.01270742 O.02095106 O.12960673 O.20314535 O.20737027 O.47915205 O.53806153 http://www.streetinsider.com/Management+Changes/AN2+Therapeutics+names+Cameron+Trenor+as+chief+medical+officer/26964064.html <p>AN2 Therapeutics, Inc. (Nasdaq: ANTX) has appointed Cameron Trenor, M.D., as chief medical officer, the clinical-stage biopharmaceutical company announced in a press release.</p> <p>Dr. Trenor most recently served as chief medical officer at Cellarity, where he oversaw the company's first investigational new drug submission and the initiation of a global first-in-human clinical study. Before that, he was executive medical director at Forma Therapeutics, which was later acquired by Novo Nordisk, where he led global clinical development for etavopivat through Phase 3. Earlier in his career, he held clinical and translational roles at Novartis Institutes for BioMedical Research.</p> <p>Dr. Trenor continues to practice http://www.streetinsider.com/Management+Changes/AN2+Therapeutics+names+Cameron+Trenor+as+chief+medical+officer/26964064.html Mon, 24 Aug 2026 07:00:58 -0400 A.13777776 A.20922990 A.24325885 A.35954321 A.39894163 A.50114147 A.50201820 ANTX O.00048977 O.01270742 O.02095106 O.12960673 O.20314535 O.20737027 O.47915205 O.53806153 http://www.streetinsider.com/Management+Changes/AN2+Therapeutics+names+Cameron+Trenor+as+chief+medical+officer/26964064.html <p>AN2 Therapeutics, Inc. (Nasdaq: ANTX) has appointed Cameron Trenor, M.D., as chief medical officer, the clinical-stage biopharmaceutical company announced in a press release.</p> <p>Dr. Trenor most recently served as chief medical officer at Cellarity, where he oversaw the company's first investigational new drug submission and the initiation of a global first-in-human clinical study. Before that, he was executive medical director at Forma Therapeutics, which was later acquired by Novo Nordisk, where he led global clinical development for etavopivat through Phase 3. Earlier in his career, he held clinical and translational roles at Novartis Institutes for BioMedical Research.</p> <p>Dr. Trenor continues to practice http://www.streetinsider.com/Management+Changes/AN2+Therapeutics+names+Cameron+Trenor+as+chief+medical+officer/26964064.html Mon, 24 Aug 2026 07:00:58 -0400 A.13777776 A.20922990 A.24325885 A.35954321 A.39894163 A.50114147 A.50201820 ANTX O.00048977 O.01270742 O.02095106 O.12960673 O.20314535 O.20737027 O.47915205 O.53806153 http://www.streetinsider.com/Management+Changes/AN2+Therapeutics+names+Cameron+Trenor+as+chief+medical+officer/26964064.html <p>AN2 Therapeutics, Inc. (Nasdaq: ANTX) has appointed Cameron Trenor, M.D., as chief medical officer, the clinical-stage biopharmaceutical company announced in a press release.</p> <p>Dr. Trenor most recently served as chief medical officer at Cellarity, where he oversaw the company's first investigational new drug submission and the initiation of a global first-in-human clinical study. Before that, he was executive medical director at Forma Therapeutics, which was later acquired by Novo Nordisk, where he led global clinical development for etavopivat through Phase 3. Earlier in his career, he held clinical and translational roles at Novartis Institutes for BioMedical Research.</p> <p>Dr. Trenor continues to practice http://www.streetinsider.com/Management+Changes/AN2+Therapeutics+names+Cameron+Trenor+as+chief+medical+officer/26964064.html Mon, 24 Aug 2026 07:00:58 -0400 A.13777776 A.20922990 A.24325885 A.35954321 A.39894163 A.50114147 A.50201820 ANTX O.00048977 O.01270742 O.02095106 O.12960673 O.20314535 O.20737027 O.47915205 O.53806153 http://www.streetinsider.com/Management+Changes/AN2+Therapeutics+names+Cameron+Trenor+as+chief+medical+officer/26964064.html <p>AN2 Therapeutics, Inc. (Nasdaq: ANTX) has appointed Cameron Trenor, M.D., as chief medical officer, the clinical-stage biopharmaceutical company announced in a press release.</p> <p>Dr. Trenor most recently served as chief medical officer at Cellarity, where he oversaw the company's first investigational new drug submission and the initiation of a global first-in-human clinical study. Before that, he was executive medical director at Forma Therapeutics, which was later acquired by Novo Nordisk, where he led global clinical development for etavopivat through Phase 3. Earlier in his career, he held clinical and translational roles at Novartis Institutes for BioMedical Research.</p> <p>Dr. Trenor continues to practice http://www.streetinsider.com/Management+Changes/AN2+Therapeutics+names+Cameron+Trenor+as+chief+medical+officer/26964064.html Mon, 24 Aug 2026 07:00:58 -0400 A.13777776 A.20922990 A.24325885 A.35954321 A.39894163 A.50114147 A.50201820 ANTX O.00048977 O.01270742 O.02095106 O.12960673 O.20314535 O.20737027 O.47915205 O.53806153 http://www.streetinsider.com/Management+Changes/AN2+Therapeutics+names+Cameron+Trenor+as+chief+medical+officer/26964064.html <p>AN2 Therapeutics, Inc. (Nasdaq: ANTX) has appointed Cameron Trenor, M.D., as chief medical officer, the clinical-stage biopharmaceutical company announced in a press release.</p> <p>Dr. Trenor most recently served as chief medical officer at Cellarity, where he oversaw the company's first investigational new drug submission and the initiation of a global first-in-human clinical study. Before that, he was executive medical director at Forma Therapeutics, which was later acquired by Novo Nordisk, where he led global clinical development for etavopivat through Phase 3. Earlier in his career, he held clinical and translational roles at Novartis Institutes for BioMedical Research.</p> <p>Dr. Trenor continues to practice http://www.streetinsider.com/Management+Changes/AN2+Therapeutics+names+Cameron+Trenor+as+chief+medical+officer/26964064.html Mon, 24 Aug 2026 07:00:58 -0400 A.13777776 A.20922990 A.24325885 A.35954321 A.39894163 A.50114147 A.50201820 ANTX O.00048977 O.01270742 O.02095106 O.12960673 O.20314535 O.20737027 O.47915205 O.53806153 http://www.streetinsider.com/Management+Changes/AN2+Therapeutics+names+Cameron+Trenor+as+chief+medical+officer/26964064.html <p>AN2 Therapeutics, Inc. (Nasdaq: ANTX) has appointed Cameron Trenor, M.D., as chief medical officer, the clinical-stage biopharmaceutical company announced in a press release.</p> <p>Dr. Trenor most recently served as chief medical officer at Cellarity, where he oversaw the company's first investigational new drug submission and the initiation of a global first-in-human clinical study. Before that, he was executive medical director at Forma Therapeutics, which was later acquired by Novo Nordisk, where he led global clinical development for etavopivat through Phase 3. Earlier in his career, he held clinical and translational roles at Novartis Institutes for BioMedical Research.</p> <p>Dr. Trenor continues to practice http://www.streetinsider.com/Management+Changes/AN2+Therapeutics+names+Cameron+Trenor+as+chief+medical+officer/26964064.html Mon, 24 Aug 2026 07:00:58 -0400 A.13777776 A.20922990 A.24325885 A.35954321 A.39894163 A.50114147 A.50201820 ANTX O.00048977 O.01270742 O.02095106 O.12960673 O.20314535 O.20737027 O.47915205 O.53806153 http://www.streetinsider.com/Management+Changes/AN2+Therapeutics+names+Cameron+Trenor+as+chief+medical+officer/26964064.html <p>AN2 Therapeutics, Inc. (Nasdaq: ANTX) has appointed Cameron Trenor, M.D., as chief medical officer, the clinical-stage biopharmaceutical company announced in a press release.</p> <p>Dr. Trenor most recently served as chief medical officer at Cellarity, where he oversaw the company's first investigational new drug submission and the initiation of a global first-in-human clinical study. Before that, he was executive medical director at Forma Therapeutics, which was later acquired by Novo Nordisk, where he led global clinical development for etavopivat through Phase 3. Earlier in his career, he held clinical and translational roles at Novartis Institutes for BioMedical Research.</p> <p>Dr. Trenor continues to practice http://www.streetinsider.com/Management+Changes/AN2+Therapeutics+names+Cameron+Trenor+as+chief+medical+officer/26964064.html Mon, 24 Aug 2026 07:00:58 -0400 A.13777776 A.20922990 A.24325885 A.35954321 A.39894163 A.50114147 A.50201820 ANTX O.00048977 O.01270742 O.02095106 O.12960673 O.20314535 O.20737027 O.47915205 O.53806153 http://www.streetinsider.com/Management+Changes/AN2+Therapeutics+names+Cameron+Trenor+as+chief+medical+officer/26964064.html <p>AN2 Therapeutics, Inc. (Nasdaq: ANTX) has appointed Cameron Trenor, M.D., as chief medical officer, the clinical-stage biopharmaceutical company announced in a press release.</p> <p>Dr. Trenor most recently served as chief medical officer at Cellarity, where he oversaw the company's first investigational new drug submission and the initiation of a global first-in-human clinical study. Before that, he was executive medical director at Forma Therapeutics, which was later acquired by Novo Nordisk, where he led global clinical development for etavopivat through Phase 3. Earlier in his career, he held clinical and translational roles at Novartis Institutes for BioMedical Research.</p> <p>Dr. Trenor continues to practice http://www.streetinsider.com/Management+Changes/AN2+Therapeutics+names+Cameron+Trenor+as+chief+medical+officer/26964064.html Mon, 24 Aug 2026 07:00:58 -0400 A.13777776 A.20922990 A.24325885 A.35954321 A.39894163 A.50114147 A.50201820 ANTX O.00048977 O.01270742 O.02095106 O.12960673 O.20314535 O.20737027 O.47915205 O.53806153 http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+Appoints+Cameron+Trenor%2C+M.D.%2C+as+Chief+Medical+Officer/26964023.html <p class="bwalignc"> Dr. Trenor brings more than two decades of clinical, translational and drug development leadership experience advancing innovative therapies across rare diseases, hematology and oncology </p> <p> MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the appointment of Cameron Trenor, M.D., as Chief Medical Officer. </p><p> Dr. Trenor is an accomplished physician-scientist and biotechnology executive with more than 20 years of experience leading clinical and translational development programs across hematology, rare diseases, oncology, immunology and metabolic disorders. He has played key leadership roles in http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+Appoints+Cameron+Trenor%2C+M.D.%2C+as+Chief+Medical+Officer/26964023.html Mon, 24 Aug 2026 07:00:00 -0400 A.13777776 A.20922990 A.24325885 A.35954321 A.39894163 A.50114147 A.50201820 ANTX O.00048977 O.01270742 O.02095106 O.12960673 O.20314535 O.20737027 O.47915205 O.53806153 http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+Appoints+Cameron+Trenor%2C+M.D.%2C+as+Chief+Medical+Officer/26964023.html <p class="bwalignc"> Dr. Trenor brings more than two decades of clinical, translational and drug development leadership experience advancing innovative therapies across rare diseases, hematology and oncology </p> <p> MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the appointment of Cameron Trenor, M.D., as Chief Medical Officer. </p><p> Dr. Trenor is an accomplished physician-scientist and biotechnology executive with more than 20 years of experience leading clinical and translational development programs across hematology, rare diseases, oncology, immunology and metabolic disorders. He has played key leadership roles in http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+Appoints+Cameron+Trenor%2C+M.D.%2C+as+Chief+Medical+Officer/26964023.html Mon, 24 Aug 2026 07:00:00 -0400 A.13777776 A.20922990 A.24325885 A.35954321 A.39894163 A.50114147 A.50201820 ANTX O.00048977 O.01270742 O.02095106 O.12960673 O.20314535 O.20737027 O.47915205 O.53806153 http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+Appoints+Cameron+Trenor%2C+M.D.%2C+as+Chief+Medical+Officer/26964023.html <p class="bwalignc"> Dr. Trenor brings more than two decades of clinical, translational and drug development leadership experience advancing innovative therapies across rare diseases, hematology and oncology </p> <p> MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the appointment of Cameron Trenor, M.D., as Chief Medical Officer. </p><p> Dr. Trenor is an accomplished physician-scientist and biotechnology executive with more than 20 years of experience leading clinical and translational development programs across hematology, rare diseases, oncology, immunology and metabolic disorders. He has played key leadership roles in http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+Appoints+Cameron+Trenor%2C+M.D.%2C+as+Chief+Medical+Officer/26964023.html Mon, 24 Aug 2026 07:00:00 -0400 A.13777776 A.20922990 A.24325885 A.35954321 A.39894163 A.50114147 A.50201820 ANTX O.00048977 O.01270742 O.02095106 O.12960673 O.20314535 O.20737027 O.47915205 O.53806153 http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+Appoints+Cameron+Trenor%2C+M.D.%2C+as+Chief+Medical+Officer/26964023.html <p class="bwalignc"> Dr. Trenor brings more than two decades of clinical, translational and drug development leadership experience advancing innovative therapies across rare diseases, hematology and oncology </p> <p> MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the appointment of Cameron Trenor, M.D., as Chief Medical Officer. </p><p> Dr. Trenor is an accomplished physician-scientist and biotechnology executive with more than 20 years of experience leading clinical and translational development programs across hematology, rare diseases, oncology, immunology and metabolic disorders. He has played key leadership roles in http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+Appoints+Cameron+Trenor%2C+M.D.%2C+as+Chief+Medical+Officer/26964023.html Mon, 24 Aug 2026 07:00:00 -0400 A.13777776 A.20922990 A.24325885 A.35954321 A.39894163 A.50114147 A.50201820 ANTX O.00048977 O.01270742 O.02095106 O.12960673 O.20314535 O.20737027 O.47915205 O.53806153 http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+Appoints+Cameron+Trenor%2C+M.D.%2C+as+Chief+Medical+Officer/26964023.html <p class="bwalignc"> Dr. Trenor brings more than two decades of clinical, translational and drug development leadership experience advancing innovative therapies across rare diseases, hematology and oncology </p> <p> MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the appointment of Cameron Trenor, M.D., as Chief Medical Officer. </p><p> Dr. Trenor is an accomplished physician-scientist and biotechnology executive with more than 20 years of experience leading clinical and translational development programs across hematology, rare diseases, oncology, immunology and metabolic disorders. He has played key leadership roles in http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+Appoints+Cameron+Trenor%2C+M.D.%2C+as+Chief+Medical+Officer/26964023.html Mon, 24 Aug 2026 07:00:00 -0400 A.13777776 A.20922990 A.24325885 A.35954321 A.39894163 A.50114147 A.50201820 ANTX O.00048977 O.01270742 O.02095106 O.12960673 O.20314535 O.20737027 O.47915205 O.53806153 http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+Appoints+Cameron+Trenor%2C+M.D.%2C+as+Chief+Medical+Officer/26964023.html <p class="bwalignc"> Dr. Trenor brings more than two decades of clinical, translational and drug development leadership experience advancing innovative therapies across rare diseases, hematology and oncology </p> <p> MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the appointment of Cameron Trenor, M.D., as Chief Medical Officer. </p><p> Dr. Trenor is an accomplished physician-scientist and biotechnology executive with more than 20 years of experience leading clinical and translational development programs across hematology, rare diseases, oncology, immunology and metabolic disorders. He has played key leadership roles in http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+Appoints+Cameron+Trenor%2C+M.D.%2C+as+Chief+Medical+Officer/26964023.html Mon, 24 Aug 2026 07:00:00 -0400 A.13777776 A.20922990 A.24325885 A.35954321 A.39894163 A.50114147 A.50201820 ANTX O.00048977 O.01270742 O.02095106 O.12960673 O.20314535 O.20737027 O.47915205 O.53806153 http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+Appoints+Cameron+Trenor%2C+M.D.%2C+as+Chief+Medical+Officer/26964023.html <p class="bwalignc"> Dr. Trenor brings more than two decades of clinical, translational and drug development leadership experience advancing innovative therapies across rare diseases, hematology and oncology </p> <p> MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the appointment of Cameron Trenor, M.D., as Chief Medical Officer. </p><p> Dr. Trenor is an accomplished physician-scientist and biotechnology executive with more than 20 years of experience leading clinical and translational development programs across hematology, rare diseases, oncology, immunology and metabolic disorders. He has played key leadership roles in http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+Appoints+Cameron+Trenor%2C+M.D.%2C+as+Chief+Medical+Officer/26964023.html Mon, 24 Aug 2026 07:00:00 -0400 A.13777776 A.20922990 A.24325885 A.35954321 A.39894163 A.50114147 A.50201820 ANTX O.00048977 O.01270742 O.02095106 O.12960673 O.20314535 O.20737027 O.47915205 O.53806153